In the majority of ITP patients, anti-GPIIb/IIIa antibodies are present in 70% to 80% of cases, while anti-GPIbα antibodies are found in 20% to 40% of cases. This evidence concerns the gene ITGA2B and autoimmune thrombocytopenic purpura.